ストックスクリーナーアプリを入手
57.38
1.02%
0.58
プレマーケット:
58.48
1.10
+1.92%
Incyte Corp (INCY) 最新ニュース
Cytokine Release Syndrome Treatment Market Size in 7MM - openPR.com
Incyte (INCY) Sees Boosted Price Target by BofA Analyst | INCY Stock News - GuruFocus
Lobbying Update: $60,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq
Incyte Grants Restricted Stock Units to New Employees - MSN
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Incyte Can Get Novartis' Privileged Info On Drug Royalty Deal - Law360
Incyte Earnings Preview: What to Expect - Nasdaq
Incyte Earnings Preview: What To Expect - Barchart.com
Incyte to Announce Q1 2025 Financial Results on April 29 - MSN
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte (INCY) Revenue Surges, But Stock Drops 20% - GuruFocus
Global Janus Kinase Inhibitors Market Surges at 8.4% CAGR - openPR.com
Incyte to Report First Quarter Financial Results | INCY Stock Ne - GuruFocus
Incyte to Report First Quarter Financial Results - Business Wire
Judges Skeptical of Incyte's Patent Block on Sun's Alopecia Drug - Bloomberg Law News
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 - BioSpace
Incyte Can't Get Pretrial Win In Novartis Royalty Fight - Law360
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) - Yahoo Finance
Incyte Co. (NASDAQ:INCY) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
1,764,725 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Norges Bank - MarketBeat
Incyte Stock: Is INCY Outperforming the Health Care Sector? - Nasdaq
Incyte Stock: Is INCY Outperforming The Health Care Sector? - Barchart.com
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
Women in healthcare and life sciences - The Business Journals
Incyte’s SWOT analysis: stock faces patent cliff challenge amid pipeline promise - Investing.com
Meiji Yasuda Asset Management Co Ltd. Purchases 32,830 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte : U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir - MarketScreener
Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Had a Bad Week. Investors Are Used to It. - MSN
Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - MarketScreener
Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks
Compass Ion Advisors LLC Has $960,000 Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks
Why Incyte Stock Was Tanking This Week - MSN
Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India
Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com
Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance
William Blair Downgrades Incyte (BMV:INCY) - Nasdaq
Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa
William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha
Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR
1.00%
大文字化:
|
ボリューム (24 時間):